PMCB PharmaCyte Biotech, Inc.
Distress ·
PharmaCyte Biotech will miss the December 15, 2025 deadline for its quarterly report and says it will file within five calendar days. The company's latest annual report says its licensed patents have expired and that the know-how for its core technology sits with a partner, while it has cut program spending during a board review.
Nasdaq told PharmaCyte on December 1, 2025 that its stock had failed the $1.00 minimum bid price over 30 consecutive business days. The company has until June 1, 2026, and any reverse stock split would need shareholder approval. The filings give no share price or cash figure to show how far the company is from compliance.
PharmaCyte says the money is meant to support TNF's license of a light-based computing platform for cryptocurrency mining. TNF plans to change its name and ticker.
PharmaCyte agreed to sell 7,000 shares of Series C convertible preferred stock, with a $1,000 stated value each, to existing investors for $7.0 million. The preferred converts at $1.00 a share, against $4.00 for the 2023 Series B, and it carries a 7.0% quarterly dividend payable in cash.
The company said it needs more time to prepare and review its financial statements. It plans to file within 15 days of the July 29, 2025 due date.
| Line | FY ended Apr 30, 2026 | FY ended Apr 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development | $391,301 | $438,416 |
| Net income (loss) | -$19.4 million | $30.7 million |
| Cash from operations | -$5.2 million | -$3.0 million |
| Cash and equivalents | $18.6 million | $15.2 million |
| Short-term investments | $254,010 | $366,316 |
Our latest story on this, dated Dec 5, 2025: "PharmaCyte Biotech gets Nasdaq minimum bid price deficiency notice, has until June 1, 2026". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 18, 2025: "PharmaCyte Biotech agrees $7.0 million convertible preferred private placement". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 18, 2025: "PharmaCyte Biotech agrees $7.0 million convertible preferred private placement". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Dec 5, 2025: "PharmaCyte Biotech gets Nasdaq minimum bid price deficiency notice, has until June 1, 2026". The story links the filing or release it is based on. Read the story.
PharmaCyte Biotech, Inc. trades under the ticker PMCB on NASDAQ.
PharmaCyte Biotech, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for PharmaCyte Biotech, Inc. is 1157075. Its filings are on SEC EDGAR.
10,735,649 shares as of 2026-09-11, per the cover page of its 10-Q filed 2026-09-14.
Our directory records PharmaCyte Biotech, Inc. under United States.
Our directory classifies PharmaCyte Biotech, Inc. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline.
The ISIN recorded for PharmaCyte Biotech, Inc. is US71715X2036.
aibio.space lists PharmaCyte Biotech, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
$0 for the fiscal year ended Apr 30, 2026, as reported to the SEC.
PharmaCyte Biotech, Inc. reported a net loss of $19.4 million for the fiscal year ended Apr 30, 2026, and used $5.2 million of cash in operations, per its annual report to the SEC.
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio